Acquired amegakaryocytic thrombocytopenia (AAT) is a rare hematological disorder causing severe thrombocytopenia and bleeding. Previous in vitro studies postulated both cell-mediated suppression of megakaryocytopoiesis in early megakaryocytic progenitor cells and humoral-mediated suppression by anti-thrombopoietin antibodies as possible etiologies of AAT. Patients with AAT usually present with severe bleeding and thrombocytopenia that is unresponsive to steroids and intravenous immunoglobulin (IVIG). Although standard guidelines have not been established for management of AAT, a few case reports have indicated a response to immunosuppressive treatment. The prompt recognition of this disease entity is essential in view of the substantial risk of morbidity and mortality from excessive bleeding. We report a case of AAT successfully treated with equine antithymocyte globulin (ATG) and cyclosporine (CSP).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932838 | PMC |
| http://dx.doi.org/10.1155/2014/806541 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report:Clinical manifestations and therapeutic options following rhTPO-induced neutralizing antibody production in a child with immune thrombocytopenia.
Ann Hematol
December 2024
Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Recombinant human thrombopoietin (rhTPO) is commonly used to improve low platelet status in immune thrombocytopenia (ITP), as one protein product, even with a very low rate, there is still the possibility to produce neutralizing antibodies of thrombopoietin (TPO). We described a 7-year-old boy with ITP and normal TPO levels who had previously received rhTPO for 2 weeks but showed persistent thrombocytopenia and was misdiagnosed as acquired amegakaryocytic thrombocytopenia (AATP) and ineffectively treated with cyclosporine A (CsA) in combination with avatrombopag (AVA). As suspicious the TPO neutralizing antibody development as re-test of TPO level is 0, the CD20 + deletion antibody drug rituximab (RTX) was prescribed and received efficacy.
View Article and Find Full Text PDFHaematopoietic cell transplantation for 106 infants and preschoolers with acquired and inherited bone marrow failures.
Br J Haematol
December 2024
Faculdades Pequeno Príncipe, Curitiba, Paraná, Brazil.
Aplastic anaemia in infants and young children presents unique challenges due to high prevalence of inherited bone marrow failure syndromes (IBMFS) in this age group. The objective of this study is assessing clinical characteristics and outcomes of haematopoietic cell transplantation in children ≤5 years with bone marrow failure syndromes. We analysied 106 patients (66% males), median age 4.
View Article and Find Full Text PDFManagement of Acquired Amegakaryocytic Thrombocytopenia and Severe Coronary Artery Disease.
Eur J Case Rep Intern Med
September 2024
Department of Internal Medicine, University of New Mexico, Albuquerque, USA.
Article Synopsis
- - Amegakaryocytic thrombocytopenia is a rare blood disorder that severely reduces platelet production due to a lack of megakaryocytes, which can lead to serious complications, especially in patients with cardiovascular issues.
- - A case study presented a patient with chest pain diagnosed with NSTEMI, who also had severe thrombocytopenia and triple vessel disease, complicating urgent surgical options despite treatment efforts.
- - Effective management requires accurate diagnosis to differentiate amegakaryocytic thrombocytopenia from immune thrombocytopenia and emphasizes the need for interdisciplinary collaboration in treating complex cases in modern healthcare.
Acquired Amegakaryocytic Thrombocytopenia with Glycoprotein IIb/IIIa Antibody in a Patient with Mantle Cell Lymphoma.
Intern Med
September 2024
Department of Hematology, Nagano Red Cross Hospital, Japan.
Background Acquired amegakaryocytic thrombocytopenia (AAMT) is a rare disorder characterized by thrombocytopenia, marked megakaryocytic hypoplasia, and preserved other-lineage hematopoiesis in the bone marrow. The etiology of AAMT remains poorly understood owing to its rarity. Case description We encountered a diagnostically challenging case involving a 66-year-old man who showed severe thrombocytopenic bleeding with isolated megakaryocytic hypoplasia, elevated serum thrombopoietin levels, glycoprotein IIb/IIIa antibody positivity, and prolonged platelet transfusion refractoriness following mantle cell lymphoma (MCL).
View Article and Find Full Text PDFTransient Acquired Amegakaryocytic Thrombocytopenia in the Setting of Severe Sepsis: A Case Report.
Cureus
July 2024
Hematology and Oncology, Northeast Georgia Medical Center Gainesville, Gainesville, USA.
Acquired amegakaryocytic thrombocytopenia (AATP) is a rare disorder in which severely low platelet levels occur due to reduced or complete absence of megakaryocytes in the bone marrow. The pathophysiology of this disease is not fully understood, although anti-thyroid peroxidase antibodies (anti-TPO) binding to cellular-myeloproliferative leukemia (c-mpl) receptors is a proposed mechanism. Currently, no standard published guideline for treatment exists, but immunosuppressive therapies have been used based on the proposed mechanism and associated conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!